AMBQ vs MLAB

AMBQ exhibits severe financial distress signals, with a Piotroski F-Score of 1/9 indicating extreme operational weakness and no Altman Z-Score available, raising unquantified bankruptcy risk. Despite a strong gross margin of 44.26%, the company reports deep losses across all profitability metrics, including a -50.28% net profit margin and negative ROE/ROA. Insider selling of $0.55M in the last 6 months, coupled with a 34.2% decline over the past year, underscores deteriorating sentiment. While earnings surprises have been positive in recent quarters, they stem from shrinking losses rather than real profitability, and revenue growth is negligible at just 2% YoY. The stock trades at a premium valuation (Price/Sales: 7.33) despite negative earnings and no intrinsic value support.

MLAB exhibits a stable financial health profile with a Piotroski F-Score of 6/9, but it is fundamentally disconnected from its valuation. The stock trades at a massive premium to its Graham Number ($22.23) and Intrinsic Value ($4.55), with a trailing P/E of 150.54. While the forward P/E of 18.15 suggests an expected earnings recovery, the current dividend payout ratio of 98.46% is unsustainable. Long-term price performance is severely negative, indicating a persistent lack of value creation over a 5-year horizon.